

Investor Fact Sheet


First half-year 2025/26

(Unaudited Swiss GAAP FER figures)
in thousand CHF


	Half-year 2025/26	in %	Half-year 2024/25	in %	Change	in %
Sales of goods and services group	362.7	100.0	324.0	100.0	38.6	11.9
Ypsomed Delivery Systems (YDS)	266.6	73.5	220.3	68.0	46.3	21.0
Others and YDC	96.1	26.5	103.7	32.0	-7.7	-7.5
Gross profit	150.2	41.4	132.8	41.0	17.4	13.1
Operating profit	151.7	41.8	40.5	12.5	111.2	274.4
Ypsomed Delivery Systems (YDS)	86.5	32.4				
Others and YDC	65.2					
Financial income	3.6	1.0	2.1	0.7	1.5	70.5
Financial expenses	-8.1	-2.2	-6.3	-2.0	-1.7	27.0
Income taxes	-8.2	-2.3	-3.7	-1.1	-4.5	120.9
Net profit	139.1	38.4	32.6	10.1	106.5	326.7
Earnings per share (undiluted) in CHF	10.19		2.39		7.80	326.5
Operating profit	151.7	41.8	40.5	12.5	111.2	274.4
Depreciation and impairment of fixed assets	25.3		23.2		2.1	9.3
Amortisation and impairment of intangible assets	11.9		14.1		-2.2	-15.5
EBITDA (operating profit before depreciation and amortisation)	188.9	52.1	77.8	24.0	111.1	142.9
Equity ratio in %	66.8%		51.1% ¹		15.7%	
Investments in fixed assets	122.8		93.8		29.1	31.0
Investments in intangible assets	19.9		38.1		-18.1	-47.6
Number of employees (headcount)	2162		2753 ¹		-591	-21.5
Full-time equivalents	2085		2644 ¹		-560	-21.2

¹ As of 31 March 2025

Sales at group level



EBIT at group level



Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group are available in the Semiannual Report 2025/26 and on www.ypsomed.ch.

Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

Ypsomed Holding AG // Sam Ghezelbash // Head of Investor Relations and M&A //
Brunnmattstrasse 6 // 3401 Burgdorf // Telephone +41 76 228 51 45 //
sam.ghezelbash@ypsomed.com // www.ypsomed.ch

YPSOMED
SELFCARE SOLUTIONS